Nelumal A, a novel FXR agonist, attenuates oxidative stress by upregulating local antioxidant enzymes (including catalase, glutathione peroxidase, and superoxide dismutase) to inhibit azoxymethane (AOM)/DSS-induced CRC (Miyazaki et al., 2021). This evidence concerns the gene NR1H4 and colorectal carcinoma.